Latest journalAll journals
EMJ Neurology 11 [Supplement 1] 2023
While people with multiple sclerosis (MS) are not more likely to contract COVID-19, the incidences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related complications may be higher for people with MS who have comorbidities or who are taking certain disease modifying therapies (DMT).
Latest articlesAll articles
Hearts are NOT Made to Be Broken: Expert Opinion on Amyloid Light-Chain Cardiac Amyloidosis
Congress reviewsAll congress reviews
Review of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022
THIS YEAR’S European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress was the 38th, and the first ever hybrid congress organised by ECTRIMS. The congress, which is the world’s largest for research into the pathogenesis, diagnosis, and treatment in multiple sclerosis (MS) and related neurological disorders, is held in collaboration with Rehabilitation in Multiple Sclerosis (RIMS).
Progressive Multiple Sclerosis: Time to Trial Something New?
PROGRESSIVE multiple sclerosis (MS) posed an important topic of discussion at the 38th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, held in Amsterdam, the Netherlands, between 26th–28th October 2022. Throughout the engaging session on progressive MS, chaired by Kathy Smith, National Multiple Sclerosis Society, New York, USA, and Jan Meilof, University of Groningen, the Netherlands, key learning and focus points to consider for the future of clinical trials and treatments were summarised and spotlighted.